Ashton JJ, Kammermeier J, Spray C Impact of COVID-19 on diagnosis and management of paediatric inflammatory bowel disease during lockdown: a UK nationwide study. Arch Dis Child. 2020; 105:(12)1186-1191

British Society of Paediatric Gastroenterology, Hepatology and Nutrition IBD Working Group. Coronavirus (SARS-CoV-2) and COVID-19 in children with IBD. Position statement: guidance for returning to school. 2020. (accessed 8 July 2021)

Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Biomed. 2020; 91:(1)157-160

Dobrusin A, Hawa F, Gladshteyn M Gastroenterologists and patients report high satisfaction rates with telehealth services during the novel coronavirus 2019 pandemic. Clin Gastroenterol Hepatol. 2020; 18:(11)2393-2397.e2

Kennedy NA, Hansen R, Younge L Organisational changes and challenges for inflammatory bowel disease services in the UK during the COVID-19 pandemic. Frontline Gastroenterol. 2020a; 11:(5)343-350

Kennedy NA, Jones GR, Lamb CA BSG guidance for management of inflammatory bowel disease during the COVID-19 pandemic. Gut. 2020b; 69:(6)984-990

Levine A, Koletzko S, Turner D ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. J Pediatr Gastroenterol Nutr. 2014; 58:(6)795-806

Molander P, Jussila A, Toivonen T, Mäkkeli P, Alho A, Kolho KL. The impacts of an inflammatory bowel disease nurse specialist on the quality of care and costs in Finland. Scand J Gastroenterol. 2018; 53:(12)1463-1468

Rosen MJ, Dhawan A, Saeed SA. Inflammatory bowel disease in children and adolescents. JAMA Pediatr. 2015; 169:(11)1053-1060

Vavricka SR, Schoepfer A, Scharl M, Lakatos PL, Navarini A, Rogler G. Extraintestinal manifestations of inflammatory bowel disease. Inflamm Bowel Dis. 2015; 21:(8)1982-1992

Wosik J, Fudim M, Cameron B Telehealth transformation: COVID-19 and the rise of virtual care. J Am Med Inform Assoc. 2020; 27:(6)957-962

Zhang YZ, Li YY. Inflammatory bowel disease: pathogenesis. World J Gastroenterol. 2014; 20:(1)91-99

Review of a paediatric inflammatory bowel disease service during the pandemic and the impact of the CNS role

22 July 2021
Volume 30 · Issue 14



Inflammatory bowel disease (IBD) is a chronic relapsing and remitting condition. The COVID-19 pandemic has severely disrupted provision of medical care across the world. IBD clinical nurse specialists (CNSs) played a pivotal role in the care of children with IBD during the pandemic national lockdown and in the recovery phase. This article aims to look at the impact of COVID-19 on the paediatric IBD service in one children's hospital and the effect on the IBD CNSs' workload.


A retrospective review of clinical notes and the service's IBD database from January 2019 to September 2020.


There was a significant increase in the number of email and telephone contacts to the IBD CNS team during lockdown. There was an increase in virtual clinics, and an increase in new IBD patients coming to the service, but a reduction in the number of face-to-face consultant clinics.


COVID-19 has disrupted medical services to children with IBD and led to a reduction in face-to-face activities but has also led to a significant increase in virtual activities. CNSs have taken up a wider role to cover patient care during a time of both medical and nursing redeployment.

Inflammatory bowel disease (IBD) is an umbrella term covering two main conditions, Crohn's disease and ulcerative colitis (Levine et al, 2014). The aetiology of IBD is as yet unknown, but genetics, environment, gut microbiome and the individual's immune system are thought to have a role in its development (Zhang and Li, 2014). IBD can affect both children and adults and commonly presents with gastrointestinal (GI) manifestations such as diarrhoea, urgency to pass stools, blood and mucous in the stools, abdominal pain and fatigue. There are also extra-intestinal manifestations that can affect organs outside the GI tract such as skin, joints and eyes (Vavricka et al, 2015). IBD is characterised by relapsing and remitting symptoms that can lead to periods of unexpected symptom exacerbation. Although there is no cure, many patients with IBD are on long-term medications to help control the inflammation and, therefore, their symptoms. Many medications used to treat IBD can modulate the immune system and most children take more than one medicine to achieve and maintain clinical remission (Rosen et al, 2015).

Register now to continue reading

Thank you for visiting British Journal of Nursing and reading some of our peer-reviewed resources for nurses. To read more, please register today. You’ll enjoy the following great benefits:

What's included

  • Limited access to clinical or professional articles

  • Unlimited access to the latest news, blogs and video content